SecBot SecBot
PRESS-RELEASE ·Filed Sep 3, 2026

BIIB

Biogen Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The data are incrementally positive but not a stock-moving catalyst, the Phase 3 EMPEROR readout in Q3 2027 is the key binary event. Monitor for any regulatory updates or changes to the NDA timeline. The 4-year durability data de-risks the mechanism modestly but does not change the probability of success for the pivotal study.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$220.83
T+0 close · Sep 3, 2026 · via day close
Latest settled
+1.25%
T+20 · $223.59 · next T+60 in 14d
Vs SPY
+0.65%
α at T+20
Latest observation
+18.01%
T+49 · FF3 residual α
  1. T+0 · Sep 4 $220.83entry
  2. T+1 · 2mo ago −3.77%α −3.22% · $212.50
  3. T+5 · 2mo ago −1.57%α −0.36% · $217.36
  4. T+20 · 6w ago +1.25%α +0.65% · $223.59
  5. T+50 · todayOpen
  6. T+60 · in 14d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen in Dravet syndrome at the European Epilepsy Congress, showing durable seizure reductions and cognitive/behavioral improvements. The Phase 3 EMPEROR study data readout is anticipated in Q3 2027, with a rolling NDA submission planned for H2 2027. This is a clinical update with no financial terms disclosed, and the stock-moving catalyst remains the Phase 3 results over a year away.

Key Facts

  • 4-year OLE data showed 93% (75/81) of eligible patients continued treatment; 77% (58/75) remained at data cutoff
  • Statistically significant improvements in cognition and behavior at 1, 2, 3, and 4 years vs OLE baseline
  • Substantial reductions in generalized tonic-clonic and focal-to-bilateral tonic-clonic seizures through 3 years
  • Quality of life improvements demonstrated through 28 months via EQ-VAS
  • Phase 3 EMPEROR study (n=162 in primary analysis population) data readout expected Q3 2027
  • Rolling NDA submission to FDA planned for H2 2027
  • Zorevunersen generally well tolerated; >930 doses administered as of July 31, 2026
  • Elevated CSF protein in ~94% of patients, 59% as treatment-emergent AE; no serious clinical manifestations or hydrocephalus
  • Stoke retains US/Canada/Mexico rights; Biogen has rest-of-world commercialization rights

Financial Impact

No financial terms or deal values disclosed in this press release. The collaboration structure (Stoke retains North America, Biogen rest-of-world) was previously announced.

Risk Factors

  • Phase 3 EMPEROR study may fail to replicate Phase 1/2a results
  • Elevated CSF protein, while asymptomatic to date, could become a safety signal in larger/longer trials
  • Competing Dravet syndrome therapies (e.g., fenfluramine, stiripentol, cannabidiol) may erode market opportunity
  • Regulatory approval timeline could slip beyond H2 2027
  • Commercialization depends on partnership execution between Stoke and Biogen

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3356336

Track record

34 reports on BIIB

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Viewing Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026